ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference

08 Jan 2026 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)

29 Dec 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 Dec 2025 16:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

02 Dec 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics, Inc. Announces CFO Transition

20 Nov 2025 16:05:00 By Nasdaq GlobeNewswire

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

05 Nov 2025 16:05:02 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

29 Oct 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

27 Oct 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Oct 2025 17:51:06 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

18 Sep 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

04 Sep 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

28 Aug 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

26 Aug 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

12 Aug 2025 16:05:19 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

06 Aug 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

04 Aug 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

28 Jul 2025 06:00:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

18 Jul 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

16 Jul 2025 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

11 Jul 2025 07:30:00 By Nasdaq GlobeNewswire